Flow Cytometry Market worth $10.57 billion by 2034 - Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 21, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Flow Cytometry Market is projected to reach USD 10.57 billion by 2034 from USD 5.56 billion in 2026, at a CAGR of 8.4% during the forecast period.

Browse 722 market data Tables and 59 Figures spread through 511 Pages and in-depth TOC on "Flow Cytometry Market - Global Forecast to 2034"

Flow Cytometry Market Size & Forecast:

• Market Size Available for Years: 2026–2034
• 2026 Market Size: USD 5.56 billion
• 2034 Projected Market Size: USD 10.57 billion
• CAGR (2026–2034): 8.4%

Flow Cytometry Market Trends & Insights:

• By region, North America accounted for the largest share of 42.0% of the flow cytometry market in 2025. Growth in the region is driven by strong biomedical research and clinical laboratory infrastructure, high adoption of high-parameter and spectral flow cytometry, sustained investments in oncology, immunology, hematology, and cell & gene therapy, and the presence of leading flow cytometry instrument, reagent, and life sciences companies.
• By technology, cell-based flow cytometry accounted for the largest share of 74.9% of the flow cytometry market in 2025. This is attributed to its broad use in immunophenotyping, cell counting, apoptosis and cell cycle analysis, cell viability assessment, intracellular staining, functional assays, and cell sorting across research, clinical, and biopharmaceutical applications.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584

The flow cytometry market is expanding as pharmaceutical and biotechnology companies, clinical laboratories, CROs, and academic research institutes increasingly adopt flow cytometry for drug discovery, immunology research, oncology, hematology, cell and gene therapy, and translational studies. Flow cytometry platforms are widely used for immunophenotyping, cell counting, viability assessment, apoptosis and cell cycle analysis, intracellular marker detection, functional assays, and rare-cell analysis. Rising demand for high-parameter, high-throughput, and reproducible cellular analysis is accelerating the adoption of multicolor and spectral flow cytometry systems, advanced cell sorters, fluorophore-conjugated antibodies, and application-specific assay kits. In addition, the growing use of automated workflows, standardized antibody panels, AI-assisted data analysis, and high-dimensional immune profiling is improving analytical efficiency, data consistency, and interpretation of complex cellular populations, thereby supporting broader adoption of flow cytometry across research, clinical, and biopharmaceutical applications.

By application, the research applications segment held the largest share of the flow cytometry market in 2025.

By application, the flow cytometry market is segmented into research, clinical, pharmaceutical & biotechnology, and industrial applications. In 2025, research applications accounted for the largest market share, supported by the extensive use of flow cytometry in immunology, oncology, stem cell research, infectious disease studies, and basic cell biology. Flow cytometry is widely employed in academic and research institutes for immunophenotyping, cell counting, cell viability assessment, apoptosis and cell cycle analysis, intracellular staining, functional assays, and rare-cell detection. The growing adoption of high-parameter and spectral flow cytometry is enabling researchers to analyze increasingly complex cellular populations with greater resolution. In addition, expanding single-cell research, increasing use of multicolor antibody panels, and rising demand for advanced cell sorting in translational and preclinical studies continue to strengthen the dominance of research applications in the flow cytometry market.

By technology, the cell-based flow cytometry segment held the largest share of the flow cytometry market in 2025.

By technology, the flow cytometry market is segmented into cell-based flow cytometry and bead-based flow cytometry. In 2025, cell-based flow cytometry accounted for the largest market share, primarily due to its extensive use in direct characterization and functional assessment of heterogeneous cell populations across research, clinical, and biopharmaceutical applications. The technology is widely used for immunophenotyping, cell counting, viability assessment, apoptosis and cell cycle analysis, intracellular marker detection, functional assays, and rare-cell analysis. Its ability to simultaneously evaluate multiple cellular parameters at the single-cell level has made it an essential tool in immunology, oncology, hematology, infectious disease research, and cell and gene therapy development. Growing adoption of high-parameter and spectral flow cytometry, expansion of multicolor antibody panels, and increasing demand for detailed immune and tumor profiling are further supporting the dominant position of cell-based flow cytometry in the market.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=65374584

By region, North America accounted for the largest share of the flow cytometry market in 2025.

In 2025, North America held the largest share of the flow cytometry market, supported by its well-established biomedical research infrastructure, strong presence of pharmaceutical and biotechnology companies, and widespread adoption of advanced cell analysis technologies. The region has a high concentration of academic research institutes, cancer centers, clinical laboratories, CROs, and biopharmaceutical manufacturers using flow cytometry across immunology, oncology, hematology, infectious disease research, and cell and gene therapy development. Increasing adoption of high-parameter and spectral flow cytometry, growing demand for multiparameter immune profiling, and expanding use of flow cytometry in translational research and clinical diagnostics continue to support market growth. In addition, sustained investments in life sciences research and increasing integration of automation and advanced data analysis tools are strengthening North America's leading position in the flow cytometry market.

Key Players

Leading players in the Flow Cytometry companies include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (US), Koninklijke Philips N.V. (Netherlands), Merck KGaA (Germany), Bio SB (US), and Sakura Finetek Japan Co., Ltd. (Japan).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65374584

Flow Cytometry Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The flow cytometry market is witnessing increasing strategic investment, driven by portfolio consolidation, expansion into spectral and high-parameter cytometry, and growing demand for cell analysis technologies in clinical diagnostics, biopharmaceutical development, and cell & gene therapy. Investment activity is increasingly centered on acquiring established instrument and reagent portfolios, strengthening recurring consumables revenues, and expanding access to regulated laboratory workflows. For instance, in July 2025, Waters Corporation (US) announced a combination with BD's Biosciences & Diagnostic Solutions business, which was completed in February 2026. The transaction was valued at approximately USD 17.5 billion and added BD's flow cytometry instruments and reagents to Waters' broader life science and diagnostics portfolio, highlighting the strategic value of flow cytometry in high-growth analytical and clinical markets.

Revenue Shift Context

The flow cytometry market is witnessing a gradual revenue shift from conventional, lower-parameter instruments toward higher-growth categories such as high-parameter analyzers, spectral flow cytometry, advanced cell sorters, software, and specialized reagents & consumables. The global flow cytometry market is projected to increase from USD 5.56 billion in 2026 to USD 10.57 billion by 2034, at a CAGR of 8.4%, with a growing share of incremental revenue expected to come from complex antibody-dye conjugates, multiplex assays, high-dimensional analysis platforms, and application-specific workflows. Meanwhile, conventional flow cytometers and standard benchtop systems continue to represent an important installed base, but newer spectral, high-plex, and automated platforms are gaining adoption across research, clinical, and biopharmaceutical settings.

Mergers & Acquisitions

Mergers & acquisitions in the flow cytometry market are being driven by the need to strengthen instrument and reagent portfolios, expand capabilities in high-parameter and spectral cytometry, and broaden access to clinical, biopharmaceutical, and cell & gene therapy workflows.

FLOW CYTOMETRY MARKET: MERGERS & ACQUISITIONS, JANUARY 2023–JULY 2026

Company Revenue Share Details

The top five players collectively account for approximately 65–70% of the global flow cytometry market, indicating a highly consolidated competitive landscape. This concentration reflects the strong installed base, broad product portfolios, recurring reagent and consumable revenues, established customer relationships, and global commercial reach of major market participants. Companies such as BD, Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Sony Corporation, Bio-Rad Laboratories, Inc., Miltenyi Biotec, Cytek Biosciences, Inc., Sysmex Corporation, and Sartorius AG collectively shape the competitive environment through their presence across flow cytometry instruments, reagents & consumables, software, accessories, and related services. Their continued focus on high-parameter and spectral flow cytometry, clinical applications, automation, and specialized cell-analysis workflows further reinforces the market's consolidated nature.

Browse Adjacent Market: Biotechnology Market Research Reports &Consulting

See More Latest Biotechnology Reports:

Esoteric Testing Market  by Type (Endocrinology, Oncology, Neurology, Genetic Tests, Autoimmune, Infectious Diseases), Technology (ELISA, CLIA, Flow Cytometry, NGS, RT-PCR, Chromatography, Spectrometry), Specimen (Blood, Urine) - Global Forecast to 2029

Sepsis Diagnostics Market by Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/flow-cytometry-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/flow-cytometry.asp

SOURCE MarketsandMarkets